1. 1421PClinical characterization of rare EGFR mutations in non-small cell lung cancer and in silico prediction of drug sensitivity. (23rd October 2018) Authors: Ikemura, S; Yasuda, H; Matsumoto, S; Kamada, M; Betsuyaku, T; Okuno, Y; Goto, K; Tsuchihara, K; Soejima, K Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 1487PLURET: Final survival results of the phase II trial of vandetanib in patients with advanced RET-rearranged non-small cell lung cancer. (23rd October 2018) Authors: Yoh, K; Seto, T; Satouchi, M; Nishio, M; Yamamoto, N; Murakami, H; Nogami, N; Kuroda, S; Nomura, S; Sato, A; Tsuchihara, K; Kohno, T; Matsumoto, S; Goto, K Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P-034PARADIGM study: A multicenter, randomized, phase III study of mFOLFOX6 plus panitumumab or bevacizumab as first-line treatment in patients with RAS (KRAS/NRAS) wild-type metastatic colorectal cancer. (2nd July 2019) Authors: Muro, K; Uetake, H; Tsuchihara, K; Shitara, K; Yamazaki, K; Ota, M; Oki, E; Sato, T; Naitoh, T; Komatsu, Y; Kato, T; Yamanaka, K; Mori, I; Soeda, J; Hihara, M; Yamanaka, T; Akagi, K; Ochiai, A; Yoshino, T Journal: Annals of oncology Issue: Volume 30(2019)Supplement 4 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗